Wegovy's cardiovascular indication rests on a large outcomes trial described in its label, in which 8,803 patients were exposed to Wegovy for a median of 37.3 months and 8,801 to placebo for a median of 38.6 months, with a primary endpoint of time to first cardiovascular death, nonfatal myocardial infarction or nonfatal stroke
To view or add a comment, sign in Blue Cross Blue Shield of Texas (BCBSTX) governs Urine Drug Testing/Screening (UDS) under two primary policies: CPCP020 (Drug Testing Policy) and CPCPLAB070 (Prescription Medication and Illicit Drug Testing)
A: Weight may return if healthy habits are not maintained
While CMSs proposal is welcome news, its unclear what will happen next, as the next administration will have the final say as to whether the rule is promulgated
Try to get at least 30 minutes of exercise most days of the week
Tirzepatide is a medication that has been shown to aid in weight loss